Fusen Pharmaceutical Co Ltd
HKEX:1652
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fusen Pharmaceutical Co Ltd
HKEX:1652
|
CN |
Balance Sheet
Balance Sheet Decomposition
Fusen Pharmaceutical Co Ltd
Fusen Pharmaceutical Co Ltd
Balance Sheet
Fusen Pharmaceutical Co Ltd
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
21
|
84
|
|
| Cash |
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
21
|
84
|
|
| Short-Term Investments |
31
|
244
|
475
|
561
|
331
|
313
|
82
|
133
|
36
|
21
|
0
|
|
| Total Receivables |
209
|
123
|
109
|
120
|
201
|
240
|
259
|
311
|
328
|
277
|
122
|
|
| Accounts Receivables |
209
|
123
|
109
|
120
|
68
|
50
|
56
|
69
|
66
|
61
|
122
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
133
|
190
|
202
|
242
|
262
|
215
|
0
|
|
| Inventory |
107
|
101
|
101
|
141
|
88
|
105
|
122
|
111
|
162
|
137
|
98
|
|
| Other Current Assets |
808
|
477
|
69
|
62
|
54
|
2
|
47
|
59
|
41
|
25
|
191
|
|
| Total Current Assets |
1 156
|
945
|
753
|
884
|
674
|
660
|
509
|
614
|
567
|
460
|
495
|
|
| PP&E Net |
169
|
172
|
165
|
154
|
379
|
486
|
506
|
530
|
562
|
621
|
550
|
|
| PP&E Gross |
169
|
172
|
165
|
154
|
379
|
486
|
506
|
530
|
562
|
621
|
0
|
|
| Accumulated Depreciation |
81
|
86
|
101
|
116
|
142
|
159
|
113
|
123
|
147
|
218
|
0
|
|
| Intangible Assets |
31
|
30
|
29
|
118
|
17
|
1
|
1
|
0
|
23
|
28
|
28
|
|
| Goodwill |
0
|
0
|
0
|
0
|
7
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
92
|
86
|
216
|
195
|
164
|
58
|
72
|
|
| Other Long-Term Assets |
5
|
5
|
5
|
7
|
8
|
8
|
8
|
11
|
28
|
71
|
118
|
|
| Other Assets |
0
|
0
|
0
|
0
|
7
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
1 361
N/A
|
1 151
-15%
|
951
-17%
|
1 163
+22%
|
1 176
+1%
|
1 241
+6%
|
1 239
0%
|
1 350
+9%
|
1 344
0%
|
1 238
-8%
|
1 263
+2%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
109
|
102
|
164
|
168
|
123
|
148
|
|
| Accrued Liabilities |
196
|
281
|
235
|
193
|
122
|
133
|
120
|
121
|
109
|
131
|
427
|
|
| Short-Term Debt |
617
|
571
|
360
|
0
|
0
|
179
|
141
|
150
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
100
|
190
|
0
|
22
|
78
|
238
|
304
|
294
|
|
| Other Current Liabilities |
204
|
142
|
137
|
158
|
149
|
128
|
105
|
209
|
150
|
213
|
8
|
|
| Total Current Liabilities |
1 017
|
995
|
732
|
451
|
461
|
548
|
489
|
722
|
665
|
772
|
877
|
|
| Long-Term Debt |
150
|
29
|
32
|
90
|
20
|
20
|
78
|
0
|
106
|
79
|
7
|
|
| Deferred Income Tax |
0
|
0
|
0
|
2
|
7
|
7
|
5
|
4
|
0
|
0
|
0
|
|
| Minority Interest |
5
|
6
|
2
|
2
|
8
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Other Liabilities |
1
|
1
|
5
|
4
|
7
|
8
|
11
|
11
|
10
|
18
|
21
|
|
| Total Liabilities |
1 172
N/A
|
1 030
-12%
|
771
-25%
|
549
-29%
|
503
-8%
|
582
+16%
|
581
0%
|
736
+27%
|
780
+6%
|
868
+11%
|
904
+4%
|
|
| Equity | ||||||||||||
| Common Stock |
71
|
72
|
1
|
7
|
7
|
7
|
6
|
6
|
6
|
6
|
6
|
|
| Retained Earnings |
113
|
50
|
110
|
211
|
273
|
363
|
378
|
346
|
311
|
124
|
353
|
|
| Additional Paid In Capital |
0
|
0
|
70
|
384
|
376
|
275
|
259
|
247
|
231
|
224
|
0
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
5
|
0
|
0
|
12
|
18
|
16
|
14
|
15
|
15
|
15
|
0
|
|
| Total Equity |
190
N/A
|
121
-36%
|
181
+49%
|
614
+240%
|
673
+10%
|
659
-2%
|
658
0%
|
614
-7%
|
564
-8%
|
370
-34%
|
359
-3%
|
|
| Total Liabilities & Equity |
1 361
N/A
|
1 151
-15%
|
951
-17%
|
1 163
+22%
|
1 176
+1%
|
1 241
+6%
|
1 239
0%
|
1 350
+9%
|
1 344
0%
|
1 238
-8%
|
1 263
+2%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
600
|
600
|
600
|
800
|
800
|
770
|
765
|
758
|
745
|
739
|
739
|
|